Takeda Pharmaceutical Co Ltd - Form 6-K Summary
Business Context and Reporting Period
This Form 6-K reports the resolutions passed at the 149th Annual General Meeting of Shareholders held on June 25, 2025. The filing covers the conclusion of the 148th fiscal year, which ran from April 1, 2024, to March 31, 2025.
Key Financial Metrics
The filing confirms the approval of the appropriation of surplus for the 148th fiscal year. The specific financial metrics are as follows:
- Dividend: 98 JPY per share.
- Director Bonuses: A total amount within 460 million JPY approved for two eligible directors (excluding overseas and external directors).
- Revenue, Profit, Cash Flow, Debt, and Liquidity: The filing text does not provide specific values for these metrics; it only references the reporting of the Consolidated and Unconsolidated Financial Statements.
Material Changes
The filing does not detail material changes in financial performance compared to the prior period. It confirms that the Business Report and Financial Statements for the 148th fiscal year were reported on and audited.
Guidance, Outlook, and Governance
Governance Resolutions:
- Dividend Approval: The year-end dividend of 98 JPY per share was approved as originally proposed.
- Director Elections: Ten directors were re-elected, including President Christophe Weber. Seven of the re-elected directors are classified as External Directors.
- Compensation: Bonus payments totaling up to 460 million JPY were approved for two specific directors.
Outlook and Risks: The filing text does not provide management commentary, future guidance, risk factors, or contingencies.
Key Facts for Investor Verification
- Verify the full Consolidated Financial Statements for the fiscal year ended March 31, 2025, to assess revenue, profit, and cash flow performance.
- Confirm the total dividend payout based on the 98 JPY per share rate and the company's outstanding share count.
- Review the composition of the newly elected board, noting the seven External Directors.
- Check the specific allocation of the 460 million JPY director bonus pool.